Tag: Sanofi

EU Granted Marketing Authorization for Sanofi and Lexicon’s Zynquista

sanofi
The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin), developed by Sanofi and Lexicon. Zynquista is now approved in the European Union, at once-daily doses of 200...

Sanofi and Alnylam Agreed to Conclude and Option Phase of 2014 RNAi Therapeutics Collaboration

Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vut...

Sanofi Plans Fly Supply of Flu Vaccine to UK after Brexit

Drugs company Sanofi has plans to fly supplies of flu vaccine into the UK if other transport routes are disrupted after the country leaves the EU. Hugo Fry, the managing director of its UK arm, tol...

FDA Does not Approve Sanofi and Lexicon Application for Zynquista

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista™ (sotagliflozin), a dual SGLT1 and SGLT2 inhibitor ...

EC Approved New Indication for Sanofi’s Praluent

Praluent is the only EU-approved PCSK9 inhibitor with cardiovascular outcomes data that showed an association with reduced death from any cause. The European Commission (EC) has approved a new indi...

Seeking of First Approval for Bio Med Treating CRSwNP

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for adul...

Zenetiva Helps to Rise New Talents in Drug R&D

The Parc (Pharmaceutical Applied Research Center) is marking its five-year anniversary by launching The Parc Awards at a ceremony held at Zentiva Headquarters in Prague on March 5th. The Parc is a uni...

EMA Comittee Backs Sanofi and Lexicon Diabetes Med

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of Zynquista™ (sotagliflozin), developed by Sanofi a...

Sanofi and Regeneron Present Positive Opinion of CHMP for Asthma Treatment

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupi...

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

Sanofi and Regeneron Disagree Amgen to Keep Patents

Sanofi and Regeneron Pharmaceuticals Inc. announced they strongly disagree with certain aspects of jury verdict from the U.S. District Court for the District of Delaware. The jury upheld the validity ...

Amgen Keeps Patents Related to PCSK9 antibodies

Amgen announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amg...

Indian Company Collaborates with Sanofi in CNS Area

Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, announced a new integrated drug discovery collaboration with Sanofi in the CNS therapeutic area. The first collaboration with S...

Sanofi and Regeneron Slash Price for Praluent by 60%

Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a...

Egypt and Sanofi Discussed Expanding Cooperation in Africa

Egyption Public Business Sector Minister Hisham Tawfiq said that chairman of the Holding Company for Pharmaceuticals, Chemicals and Medical Supplies Ahmed Hegazi will visit Chad next week to discuss t...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...